Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05653492 · ClinicalTrials.gov registry record · Phase 2

Safety, Feasibility, and Tolerability of Sulforaphane in Children with Chronic Kidney Disease

A Phase 2 study of Pediatric Kidney Disease, sponsored by University of Rochester.

Active
Registry status
Phase 2
Development phase
12
Enrollment target
1
Study location

NCT05653492 is a Phase 2 study of Pediatric Kidney Disease that is active but no longer recruiting, run by University of Rochester. The registered enrollment target is 12 participants, below the 5,198-participant average among 4 other Pediatric Kidney Disease trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05653492, a Phase 2 study of Pediatric Kidney Disease, is active but no longer recruiting, sponsored by University of Rochester.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
12 participants
Enrollment target
1
Study location

Study Summary

This purpose of this study is to investigate potential new therapeutics in pediatric chronic kidney disease (CKD). The specific aims are to identify safe dosing and tolerability of sulforaphane (SFN) supplementation in children with moderate and advanced CKD. Secondary objectives will include preliminary exploration of changes in oxidative and inflammatory biomarkers in response to SFN supplementation in this population.

Conditions Studied

Interventions

  • DRUG Sulforaphane

Study Locations (1)

New York

  • University of Rochester Medical Center - Rochester

Trial Details

FieldValue
Enrollment Target 12 participants
Start Date 2023-05-15
Est. Completion 2025-12-31
Phase Phase 2

Sponsor

University of Rochester

636 total trials

What the Registry Record Tells You About NCT05653492

The ClinicalTrials.gov registry entry for NCT05653492 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 5,198-participant average among 4 other Pediatric Kidney Disease trials with a reported enrollment target (100% lower). The listed sponsor is University of Rochester, which has 636 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Pediatric Kidney Disease appearing as the primary indexed condition, and to 1 intervention - of which Sulforaphane is the first listed.

NCT05653492 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.

Frequently Asked Questions

What is clinical trial NCT05653492 about?

NCT05653492 is a clinical study titled "Safety, Feasibility, and Tolerability of Sulforaphane in Children with Chronic Kidney Disease". This purpose of this study is to investigate potential new therapeutics in pediatric chronic kidney disease (CKD). The specific aims are to identify safe dosing and tolerability of sulforaphane (SFN) supplementation in children with moderate and advanced CKD. Secondary objectives will include prelim...

What is the current status of trial NCT05653492?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 12 participants. The study started on 2023-05-15. Estimated completion is 2025-12-31.

What conditions does trial NCT05653492 study?

This clinical trial studies the following conditions: Pediatric Kidney Disease.

What interventions are being tested in trial NCT05653492?

The interventions under investigation include: Sulforaphane (DRUG).

Who is sponsoring clinical trial NCT05653492?

This trial is sponsored by University of Rochester, which has 636 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05653492 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Pediatric Kidney Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.